OBJECTIVE: To identify microRNAs (miRNAs) in human T cells that can explain known antiinflammatory properties of steroids. METHODS: Activated human CD4+ T cells from healthy donors were exposed to 1 μM methylprednisolone (MP) in vitro and then subjected to miRNA and messenger RNA microarray analyses. Changes in expression profiles were recorded. Using quantitative polymerase chain reaction (qPCR), flow cytometry, and enzyme-linked immunosorbent assay (ELISA), we confirmed the suppression of predicted targets, and through miRNA transfection experiments, we could suggest mechanistic links. RESULTS: We identified numerous steroid-responsive genes and miRNAs-many known and some novel-including multiple previously unknown proinflammatory genes suppressed by MP. Further studies using qPCR, flow cytometry, and ELISA demonstrated that methylprednisolone increased the expression of miRNA-98 (miR-98) and suppressed the levels of predicted targets, including interleukin-13 and 3 tumor necrosis factor receptors (TNFRs): Fas, FasL, and TNFR superfamily member 1B. Forced expression of miR-98 in T cells resulted in suppression of the same targets. CONCLUSION: The findings of this study demonstrate a link between miR-98 expression and the effects of MP and provide evidence suggesting that MP acts through miR-98 to inhibit specific proinflammatory targets. Identification of this antiinflammatory mechanism of glucocorticoids is important, since it may pave the way toward the elusive goal of dissociating adverse effects from therapeutic effects.
OBJECTIVE: To identify microRNAs (miRNAs) in human T cells that can explain known antiinflammatory properties of steroids. METHODS: Activated humanCD4+ T cells from healthy donors were exposed to 1 μM methylprednisolone (MP) in vitro and then subjected to miRNA and messenger RNA microarray analyses. Changes in expression profiles were recorded. Using quantitative polymerase chain reaction (qPCR), flow cytometry, and enzyme-linked immunosorbent assay (ELISA), we confirmed the suppression of predicted targets, and through miRNA transfection experiments, we could suggest mechanistic links. RESULTS: We identified numerous steroid-responsive genes and miRNAs-many known and some novel-including multiple previously unknown proinflammatory genes suppressed by MP. Further studies using qPCR, flow cytometry, and ELISA demonstrated that methylprednisolone increased the expression of miRNA-98 (miR-98) and suppressed the levels of predicted targets, including interleukin-13 and 3 tumor necrosis factor receptors (TNFRs): Fas, FasL, and TNFR superfamily member 1B. Forced expression of miR-98 in T cells resulted in suppression of the same targets. CONCLUSION: The findings of this study demonstrate a link between miR-98 expression and the effects of MP and provide evidence suggesting that MP acts through miR-98 to inhibit specific proinflammatory targets. Identification of this antiinflammatory mechanism of glucocorticoids is important, since it may pave the way toward the elusive goal of dissociating adverse effects from therapeutic effects.
Authors: Qi-Jing Li; Jacqueline Chau; Peter J R Ebert; Giselle Sylvester; Hyeyoung Min; Gwen Liu; Ravi Braich; Muthiah Manoharan; Juergen Soutschek; Petra Skare; Lawrence O Klein; Mark M Davis; Chang-Zheng Chen Journal: Cell Date: 2007-03-22 Impact factor: 41.582
Authors: Sven Baumann; Anja Dostert; Natalia Novac; Anton Bauer; Wolfgang Schmid; Stefanie C Fas; Andreas Krueger; Thorsten Heinzel; Sabine Kirchhoff; Günther Schütz; Peter H Krammer Journal: Blood Date: 2005-03-31 Impact factor: 22.113
Authors: To-Ha Thai; Dinis Pedro Calado; Stefano Casola; K Mark Ansel; Changchun Xiao; Yingzi Xue; Andrew Murphy; David Frendewey; David Valenzuela; Jeffery L Kutok; Marc Schmidt-Supprian; Nikolaus Rajewsky; George Yancopoulos; Anjana Rao; Klaus Rajewsky Journal: Science Date: 2007-04-27 Impact factor: 47.728
Authors: L Lanza; M Scudeletti; F Puppo; O Bosco; L Peirano; G Filaci; E Fecarotta; G Vidali; F Indiveri Journal: Clin Exp Immunol Date: 1996-03 Impact factor: 4.330
Authors: Stefan A Muljo; K Mark Ansel; Chryssa Kanellopoulou; David M Livingston; Anjana Rao; Klaus Rajewsky Journal: J Exp Med Date: 2005-07-11 Impact factor: 14.307
Authors: Haoquan Wu; Joel R Neilson; Priti Kumar; Monika Manocha; Premlata Shankar; Phillip A Sharp; N Manjunath Journal: PLoS One Date: 2007-10-10 Impact factor: 3.240
Authors: Shinji Okano; Kareem Abu-Elmagd; Danielle D Kish; Karen Keslar; William M Baldwin; Robert L Fairchild; Masato Fujiki; Ajai Khanna; Mohammed Osman; Guilherme Costa; John Fung; Charles Miller; Hiroto Kayashima; Koji Hashimoto Journal: Am J Transplant Date: 2018-04-17 Impact factor: 8.086
Authors: V M de Jong; A R van der Slik; S Laban; R van 't Slot; B P C Koeleman; A Zaldumbide; B O Roep Journal: Genes Immun Date: 2016-07-28 Impact factor: 2.676
Authors: C De Andres; M I García; H Goicoechea; M L Martínez-Ginés; J M García-Domínguez; M L Martín; F Romero-Delgado; A Benguría; M Sanjurjo; L A López-Fernández Journal: Pharmacogenomics J Date: 2016-09-27 Impact factor: 3.550
Authors: Lindsay K Smith; Arpit Tandon; Ruchir R Shah; Deepak Mav; Alyson B Scoltock; John A Cidlowski Journal: PLoS One Date: 2013-10-24 Impact factor: 3.240
Authors: Gisela Nogales-Gadea; Alba Ramos-Fransi; Xavier Suárez-Calvet; Miquel Navas; Ricard Rojas-García; Jose Luis Mosquera; Jordi Díaz-Manera; Luis Querol; Eduard Gallardo; Isabel Illa Journal: PLoS One Date: 2014-03-17 Impact factor: 3.240